ECRM_1170x120_8-1-17

regional drug chains

Chain drug’s outlook for future remains murky

Chain drug’s outlook for future remains murky

The current year is two-thirds finished, and the good news is most notable by its absence. Sales are soft, earnings elusive. Hot new items are few and far between. Growth is nowhere to be seen. Meaningful executive job shifts have been all but absent. Mergers and acquisitions have failed to materialize — and even those

Regional drug chains display prowess as innovators

Regional drug chains display prowess as innovators

Although sometimes overlooked amid the swirl of activity surrounding the largest players in retail pharmacy, regional drug chains remain an integral part of the industry. The assets and aspirations of those companies — defined as operating between four and 250 stores — along with the challenges they face, were on display at the National Association

Trade classes battle in changing pharmacy market

Trade classes battle in changing pharmacy market

NEW YORK — Competition remains fierce in the chain pharmacy industry, albeit with a decreasing number of players. If the pending acquisition of Rite Aid Corp. by Walgreens Boots Alliance Inc. goes through, the field will diminish dramatically, especially in major metropolitan areas. Depending on the number of stores WBA divests to meet antitrust requirements,

Regional drug chains look to build on strengths

Regional drug chains look to build on strengths

FORT LAUDERDALE, Fla. — Stakeholders in chain pharmacy understandably direct a lot of attention to the giants of the industry, such companies as CVS Health, Walgreens Boots Alliance, McKesson and Kroger. Yet they shouldn’t lose sight of the regional players that, in the aggregate, still account for a substantial part of the business and remain

Regional drug chains deserve more attention

The cataclysmic changes within the chain drug retailing community, whatever their ultimate implications for America’s largest drug chains and for the industry in general, are putting the country’s regional drug chains more glaringly in the spotlight. Indeed, not only are America’s smaller drug chains more professionally managed and operated than they have yet been, they